“Third-party tested” is a common claim in this category, and on its own it does not say much. What is actually being tested, and what does each test confirm? Every iSerra™ production lot is submitted for a 14-test panel prior to release, split across four categories. Here is what each one checks, in plain terms, and where each one stops.
Fourteen tests, four categories: identity and potency (2), heavy metals (4), microbial limits (6), and USP <2040> disintegration (2). Two of those categories are contamination checks, one is a composition and activity check, and one is a physical delivery check. None of them describes an outcome in the body.
The panel at a glance
- Identity — 1 test
- Potency / activity — 1 test
- Heavy metals — 4 tests
- Microbial — 6 tests
- Disintegration (USP <2040>) — 2 tests
Grouped by what they answer, that is four categories: what the material is and how active it is; whether it is contaminated by metals; whether it meets microbial criteria; and how the finished capsule physically behaves.
Identity and potency (2 tests)
One test records identity as a separate lot-testing result. A second measures functional enzyme activity in Serrapeptase Units using the USP proteolytic assay. These evidence lines are kept separate rather than inferring identity from the activity assay.
This pairing matters because identity and activity answer different questions. iSerra’s declared specification is 250,000 SPU per capsule; the measured activity result is recorded per lot rather than restated from the label — the distinction covered in Declared Potency vs. Measured Enzyme Activity.
Heavy metals (4 tests)
Four separate tests screen for heavy-metal contamination against specified limits. This is a contamination check on the finished product. It says nothing about potency and nothing about delivery, which is exactly why it is tracked as its own category rather than folded into a single undifferentiated “purity” claim.
Microbial limits (6 tests)
Six tests evaluate the sample against specified microbial criteria. This is the largest single category in the panel, which reflects how many distinct organisms and limits a microbial testing standard typically covers — not one test repeated six times.
Disintegration — USP <2040> (2 tests)
Two tests evaluate the finished capsule under USP <2040>, the United States Pharmacopeia’s disintegration standard for delayed-release dosage forms: a gastric-phase exposure followed by an intestinal-phase exposure, recording whether and when the capsule disintegrates in each.
This is a delivery test, not a potency or contamination test — the only category in the panel that speaks specifically to whether a delayed-release capsule behaves the way it is designed to. It is also strictly a physical observation in defined laboratory media; see what USP <2040> actually tests for the limits of what such a result can support.
Where the documentation lives
Identity, potency, heavy-metals, and microbial results are documented through the lot-testing process, and Valispec™ surfaces the available lot-specific verification record by lot number. Valispec™ is a lookup and access system rather than a testing process: the laboratory testing happens first and separately, and supporting documentation is shown when attached to that lot record.
Disintegration testing under USP <2040> is part of iSerra’s finished-product testing program. At time of writing, its documentation is not confirmed to be captured within that same per-lot lookup record, so it is described here on its own terms rather than folded into the Valispec™ lookup claim above.
What the panel tells you
- What is in one specific lot, confirmed by identity testing rather than assumed from the label.
- That lot’s own measured enzyme activity.
- That the lot was screened against specified heavy-metal and microbial criteria.
- How that lot’s finished capsules behaved under the disintegration standard’s two phases.
What it does not tell you
- Anything about lots other than the one tested. A panel result is a snapshot of a batch, not a claim about every bottle a company has ever shipped.
- Anything about what happens in a body. Every test in the panel is a laboratory measurement on material or on a capsule.
- Whether a result is typical. One lot’s measured figure is that lot’s figure; each released lot is assayed and documented on its own terms.
Practical takeaway
When evaluating any product’s testing claims, ask which categories were actually tested, whether results are tied to a lot you can check, and whether the lot-specific record clearly shows what is available and what is not. The count of tests is the least interesting part of a panel; the categories, the lot, and the accessibility of the record are the rest of it.
Fourteen is a number. What matters is which four questions it answers, and which questions it was never designed to.
USP proteolytic assay conventions; USP <2040> disintegration standard; ISO/IEC 17025 laboratory competence standard. Reference detail maintained on The Science.
iSerra™ per-lot 14-test panel composition: identity 1, potency/activity 1, heavy metals 4, microbial 6, disintegration 2. Identity, potency, heavy-metals, and microbial results are tracked through the lot-testing process and surfaced as available through Valispec™.
Published research on an ingredient, finished-product testing, and lot-specific testing are three different categories of evidence and are kept separate throughout the Journal. This article introduces no external findings beyond those referenced on The Science.